+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Implantable Infusion Pump - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 180 Pages
  • October 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6292437
The implantable infusion pump market size was valued at USD 19.99 billion in 2026 and is estimated to grow from USD 22.02 billion in 2027 to reach USD 35.76 billion by 2032, at a CAGR of 10.18% during the forecast period (2027-2032). This report is Segmented by Pump Type (Programmable Implantable Infusion Pumps, and More), Application (Chronic Pain Management, Spasticity Management, and More), Therapeutic Agent (Morphine, Baclofen, Ziconotide, Bupivacaine, and More), End User (Hospitals, Ambulatory Surgical Centers, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Implantable Infusion Pump Market Trends and Insights

Rising Chronic Disease Burden and Targeted Drug Delivery

Chronic pain, spasticity, cancer, and neurological disorders provide a stable demand base for the implantable infusion pump market. A 2026 study reported 52.4 new chronic pain cases per 1,000 people each year in the United States. Medtronic’s registry of 10,793 targeted drug delivery patients through October 2024 showed that 76.5% received implants for pain management and 21.2% for spasticity. Patients who live longer after spinal cord injury or multiple sclerosis can remain eligible for treatment for a longer period. Pain medicine and neurosurgery programs are giving intrathecal baclofen a more established role for refractory spasticity. Intrathecal systems also provide analgesia at drug concentrations 100 to 300 times lower than equivalent oral doses, which can reduce systemic adverse events.

Ambulatory Care and Post-Implant Management

The shift from hospital procedures toward ambulatory care is changing the operating model of the implantable infusion pump market. Lower reimbursement in ambulatory surgical centers can reduce pricing power for device manufacturers as procedure volume moves to that setting. The same shift can widen access by allowing more patients to receive treatment outside academic referral centers. Simplified refill kits, lean monitoring workflows, and compact programming tools can make ambulatory care more practical. Specialty clinics remain important because they perform routine refills and support programming after implantation. These conditions create greater value for companies that can support follow-up services as well as the device itself. The implantable infusion pump market is therefore moving toward care models that combine implantation, refilling, monitoring, and responsive clinical support. Providers can weigh these operating factors alongside the technical features of a pump when selecting a platform for ambulatory use.

Cost, Reimbursement, and Specialist Capacity

High acquisition, implantation, and follow-up costs limit adoption in several regions of the implantable infusion pump market. Reimbursement remains fragmented in parts of Asia-Pacific and Latin America, where patients may rely on private hospitals or out-of-pocket payment. The Prometra system requires refilling at intervals of no more than 90 days, which can create 4 clinical visits each year. Battery replacement procedures can add to the treatment cost for non-rechargeable pumps. Payers are increasingly assessing refill visits, replacement procedures, and complication management alongside the original device price. This assessment is particularly relevant for the implantable infusion pump market in regions where reimbursement coverage is fragmented and public systems continue to favor oral therapies. Manufacturers with complete economic evidence can better explain the financial effect of a device across the full treatment period. Limited numbers of implanting and refill specialists further concentrate access in established centers.

Other drivers and restraints analyzed in the report include:
  • Smart Pumps, Wireless Monitoring, and Miniaturized Platforms
  • Hepatic-Artery Infusion and Oncology Expansion
  • Clinical Safety and Device Management Requirements

Segment Analysis

Programmable implantable pumps represented 56.13% of revenue in 2026, giving them the largest position in the implantable infusion pump market. Clinical evidence, physician training, and approvals across pain, spasticity, and selected oncology uses support this position. The installed base of SynchroMed and Prometra devices also produces replacement-cycle revenue, since physicians and patients need a replacement option when an implanted device reaches the end of its service life. This installed base also requires recurring clinical attention for refills, programming, and long-term treatment management. This creates more predictable demand than categories that depend mainly on new implantation volumes, even when procedure growth varies across hospital systems and referral networks. Constant-rate pumps serve the hepatic-artery infusion oncology niche. Their body-heat-powered mechanics remove battery dependence during multiyear hepatic tumor management, a relevant benefit for patients who require sustained regional chemotherapy over a long treatment period.

The Intera 3000 is the only FDA-approved constant-flow implantable pump for hepatic-artery infusion therapy in the United States. Boston Scientific can use its interventional oncology sales coverage to expand the platform beyond academic cancer centers. Implantable insulin pumps remain limited because external closed-loop insulin delivery systems avoid surgery. The FDA Premarket Approval pathway and ISO 13485 certification create compliance requirements for new competitors. These requirements involve evidence, quality management, and regulatory work that existing PMA holders have already absorbed over time. As a result, a new pump platform must address more than product performance before it can compete within established clinical settings. Intrathecal pumps are the fastest-growing pump type, with the implantable infusion pump market size for this segment forecast to grow at an 11.24% CAGR from 2027 to 2032. Ziconotide use, broader baclofen indications, and reduced systemic opioid needs support this growth.

Chronic pain management held 48.57% of application revenue in 2026, the largest implantable infusion pump market share across applications. The size of the patient population supports this position, because many patients continue to need treatment after oral and systemic analgesics have not delivered adequate symptom control. Pain medicine programs use intrathecal therapy as an escalation option for patients who do not respond to systemic analgesics, which keeps chronic pain at the center of referral and treatment pathways. Spasticity management is the second-largest application. Medtronic’s registry showed that spasticity accounted for 21.2% of targeted drug delivery implantations through October 2024.

Prospective research cited in the draft showed that intrathecal baclofen reduced spasticity scores by 40.2% and improved motor function by 9.6% in cerebral palsy. Diabetes management remains a smaller use because external pumps and continuous glucose-monitoring systems avoid implantation risk and offer a mature alternative for patients who need ongoing insulin delivery. Oncology and chemotherapy are forecast to grow at an 11.79% CAGR through 2032. Results from PUMP-2 support regional chemotherapy for unresectable intrahepatic cholangiocarcinoma. The ongoing PUMP-IT trial could add evidence for hepatic-artery infusion in colorectal liver metastases. If its overall-survival endpoint is met, the study could strengthen the clinical rationale for treatment in a first-line setting. The evidence base will remain important because oncology providers require data before expanding a specialized regional chemotherapy program. This evidence could increase referral activity in surgical oncology centers.

Complete Report Scope:

  • By Pump Type
    • Programmable Implantable Infusion Pumps
    • Constant-Rate Implantable Infusion Pumps
    • Intrathecal Infusion Pumps
    • Hepatic-Artery Infusion Pumps
    • Implantable Insulin Pumps
    • Others
  • By Application
    • Chronic Pain Management
    • Spasticity Management
    • Oncology and Chemotherapy
    • Diabetes Management
    • Others
  • By Therapeutic Agent
    • Morphine
    • Baclofen
    • Ziconotide
    • Bupivacaine
    • Clonidine
    • Floxuridine
    • Others
  • By End User
    • Hospitals
    • Ambulatory Surgical Centers
    • Specialty Clinics
    • Others
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 38.46% of global revenue in 2026, the largest regional implantable infusion pump market share. The United States supports adoption through reimbursement for approved intrathecal therapy in pain and spasticity care. The region also has a substantial chronic-pain population and a developed training pipeline in pain medicine. The Boston Scientific and Intera Oncology transaction can expand hepatic-artery infusion beyond a small group of specialized cancer centers. Canada is widening access to intrathecal therapies beyond major urban areas, which can extend treatment availability outside the largest referral centers. This development remains linked to provincial payer decisions and the availability of clinicians who can manage implantation, refilling, and ongoing programming. Mexico’s private hospital sector is expanding hepatic-artery infusion capacity at a more limited pace. The opportunity remains centered on providers that can support oncology procedures and specialist follow-up rather than on broad-based adoption across the health system.

Europe is the second-largest regional block for the implantable infusion pump market. Germany and the United Kingdom support programmable pump volumes through their national health systems. France and Italy have established neurology-related implantation programs. EU Medical Device Regulation post-market clinical follow-up requirements raise compliance costs for manufacturers. The requirements also increase the evidence standard used in hospital procurement, since providers must consider post-market clinical follow-up information when comparing established and newer platforms. The implantable infusion pump market, therefore, remains more accessible to suppliers that can provide mature registry evidence and post-market documentation. This process can increase compliance costs, but it can also reduce the appeal of platforms that do not yet have comparable clinical records. This favors platforms with multi-year registry data and can limit access for less-documented entrants.

Asia-Pacific is forecast to grow at a 13.58% CAGR from 2027 to 2032, making it the fastest-growing region. China’s aging population supports demand for chronic pain and spasticity management, while faster registration activity can improve the practical availability of medical devices for providers. China and India also have growing needs related to colorectal and hepatobiliary cancers. Japan’s clinical-evidence requirements can slow entry, but its older population supports a sizable treated base. South Korea and Australia form premium subsegments where hospitals show a preference for next-generation programmable systems and related clinical support. South Korea and Australia have a demand for next-generation programmable systems. India’s tertiary oncology infrastructure is expanding and can support hepatic-artery infusion adoption. In South America, private hospital networks in São Paulo, Rio de Janeiro, and Buenos Aires account for most implantation volumes. In the Middle East and Africa, demand remains concentrated in Saudi Arabia, the UAE, Qatar, and South Africa because specialist capacity and affordability continue to constrain broader use. Brazil and Argentina lead South American volume through private hospitals, while the Middle East and Africa demand is concentrated in Saudi Arabia, the UAE, Qatar, and South Africa. Across these regions, the availability of trained implanting physicians remains as important as disease prevalence. The implantable infusion pump market cannot expand broadly where patients lack access to specialists who can implant, refill, and monitor the system. Clinical education by device suppliers can therefore shape adoption in the same way as reimbursement reform and hospital investment.


List of Companies Covered in this Report:

  • Abbott Laboratories
  • Avanos Medical
  • B. Braun
  • Baxter
  • Beckton Dickinson
  • Boston Scientific
  • DURECT Corporation
  • Flowonix Medical Inc.
  • Fresenius
  • ICU Medical
  • Infusyn Therapeutics
  • Intera Oncology Inc.
  • Johnson & Johnson
  • Medtronic
  • MicroPort
  • Nevro
  • Smiths Group
  • Teleflex
  • Terumo
  • Tricumed Medizintechnik

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Chronic Pain, Spasticity, Cancer, and Neurological Disorders
4.2.2 Demand for Targeted, Continuous, and Programmable Drug Delivery
4.2.3 Hospital-to-Home and Ambulatory Care Shift
4.2.4 Smart Pump, Wireless Telemetry, and Remote Monitoring Adoption
4.2.5 Expansion of Hepatic-Artery Infusion in Liver Oncology
4.2.6 BioMEMS and Miniaturized Micro-Dosing Platforms
4.3 Market Restraints
4.3.1 High Device, Implantation, and Follow-Up Costs
4.3.2 Infection, Catheter, Granuloma, and Mechanical-Failure Risk
4.3.3 Limited Specialist Implantation and Refill Capacity
4.3.4 Battery Replacement, Cybersecurity, and Software-Update Burden
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter’s Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Buyers
4.7.3 Bargaining Power of Suppliers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Pump Type
5.1.1 Programmable Implantable Infusion Pumps
5.1.2 Constant-Rate Implantable Infusion Pumps
5.1.3 Intrathecal Infusion Pumps
5.1.4 Hepatic-Artery Infusion Pumps
5.1.5 Implantable Insulin Pumps
5.1.6 Others
5.2 By Application
5.2.1 Chronic Pain Management
5.2.2 Spasticity Management
5.2.3 Oncology and Chemotherapy
5.2.4 Diabetes Management
5.2.5 Others
5.3 By Therapeutic Agent
5.3.1 Morphine
5.3.2 Baclofen
5.3.3 Ziconotide
5.3.4 Bupivacaine
5.3.5 Clonidine
5.3.6 Floxuridine
5.3.7 Others
5.4 By End User
5.4.1 Hospitals
5.4.2 Ambulatory Surgical Centers
5.4.3 Specialty Clinics
5.4.4 Others
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 India
5.5.3.3 Japan
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as Available, Strategic Information, Market Rank/Share for Key Companies, Products & Services, and Recent Developments)
6.3.1 Abbott Laboratories
6.3.2 Avanos Medical Inc.
6.3.3 B. Braun Melsungen AG
6.3.4 Baxter International Inc.
6.3.5 Becton, Dickinson and Company
6.3.6 Boston Scientific Corporation
6.3.7 DURECT Corporation
6.3.8 Flowonix Medical Inc.
6.3.9 Fresenius Kabi AG
6.3.10 ICU Medical Inc.
6.3.11 Infusyn Therapeutics
6.3.12 Intera Oncology Inc.
6.3.13 Johnson & Johnson
6.3.14 Medtronic plc
6.3.15 MicroPort Scientific Corporation
6.3.16 Nevro Corporation
6.3.17 Smiths Medical
6.3.18 Teleflex Incorporated
6.3.19 Terumo Corporation
6.3.20 Tricumed Medizintechnik GmbH
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Avanos Medical Inc.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • DURECT Corporation
  • Flowonix Medical Inc.
  • Fresenius Kabi AG
  • ICU Medical Inc.
  • Infusyn Therapeutics
  • Intera Oncology Inc.
  • Johnson & Johnson
  • Medtronic plc
  • MicroPort Scientific Corporation
  • Nevro Corporation
  • Smiths Medical
  • Teleflex Incorporated
  • Terumo Corporation
  • Tricumed Medizintechnik GmbH